TC Biopharm (Holdings) PLC TCBP

Healthcare Biotechnology

TC BioPharm (Holdings) plc, formerly TC BioPharm (Holdings) Limited, is a clinical-stage biopharmaceutical company. The Company is focused on developing immunotherapy products that are based on its allogeneic gamma delta T (GD-T) cell platform. Harnessing the innate ability of GD-Ts, the Company has developed a range of clinical-stage cell therapies designed to combat identified cancers and viral infections. In addition to unmodified allogenic GD-Ts for treatment of blood cancers, it is also developing a range of genetically modified chimeric antigen receptor modified T cell (CAR-T) products for treatment of solid cancers. The Company’s pipeline includes OmnImmune, ImmuniStim, TCB009, and TCB005/TCB006. OmnImmune is an allogeneic unmodified GD-T (GD-T2) cell product, used for the treatment of Acute Myeloid Leukaemia (AML). ImmuniStim is used for the treatment of coronavirus disease (COVID-19). TCB009 is developing GD-T2 based cell therapies.

NDAQ:TCBP - Post by User

TC Biopharm (Holdings) PLC

<< Previous

Bullboard Posts

Next >>

Post by whytestockson Aug 15, 2024 3:02pm

76 Views

Post# 36181152

TC BioPharm Announces Closing of $2.0 Million Public Offerin

JUST IN: $TCBP TC BioPharm Announces Closing of $2.0 Million Public OfferingTC BioPharm Announces Closing of $2.0 Million Public Offering PR Newswire EDINBURGH, Scotland , Aug. 15, 2024 /PRNewswire/ -- TC BioPharm (Holdings) PLC ("TC BioPharm" or the "Company") (NASDAQ: TCBP) a clinical stage biotechnology company developing platfor...TCBP - TC BioPharm Announces Closing of $2.0 Million Public Offering

<< Previous

Bullboard Posts

Next >>

Anaergia expands relationship with PepsiCo